Eisai acquires silodosin rights in selected markets
This article was originally published in Scrip
Kissei has licensed its alpha 1a-adrenoceptor antagonist, silodosin, to Eisai for development and marketing in 10 Asian countries plus India and Sri Lanka.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.